BIOX Bioceres Crop Solutions Corp. IFRS
Agricultural Chemicals · Nasdaq · SEC CIK 1769484 · Fiscal year ends 06/30
Financial factors as of 2025-12-31 (2026Q2), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q2*2025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 | 2025Q12024-09-30 | 2024Q4*2024-06-30 | 2024Q32024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $73.81M | $77.60M | $74.55M | $60.59M | $98.80M | $93.29M | $123.99M | $83.98M |
| Cost of revenue | $47.15M | $41.30M | $49.34M | $36.74M | $57.26M | $55.80M | $76.56M | $41.34M |
| Gross profit | $26.65M | $36.30M | $25.21M | $23.85M | $41.54M | $37.49M | $47.43M | $42.64M |
| R&D expense | $2.35M | $5.72M | $2.65M | $3.66M | $1.97M | $4.41M | $5.37M | $3.59M |
| SG&A expense | $17.14M | $23.14M | $33.64M | $26.15M | $25.35M | $30.16M | $31.50M | $27.09M |
| Operating income | $7.52M | $7.21M | -$13.46M | $933,210 | $14.36M | $2.37M | $9.48M | $13.20M |
| Interest expense | $7.95M | $9.12M | $8.14M | $6.11M | $6.43M | $7.16M | $8.16M | $7.24M |
| Pretax income | -$1.37M | -$5.37M | -$44.92M | -$5.60M | $7.30M | -$7.46M | -$6.11M | $8.82M |
| Income tax | $3.11M | $2.08M | $6.75M | -$4.01M | $636,153 | -$1.27M | -$4.03M | -$955,832 |
| Net income | -$182.47M | -$7.33M | -$47.89M | -$1.30M | $143,535 | -$6.37M | -$1.53M | $9.26M |
| EPS (basic) | -2.88 | -0.12 | — | -0.02 | 0.00 | -0.10 | — | 0.15 |
| EPS (diluted) | -2.88 | -0.12 | — | -0.02 | 0.00 | -0.10 | — | 0.14 |
| Weighted avg. shares (diluted) | — | 63.43M | — | 62.79M | 63.17M | 62.85M | — | 66.76M |
| Balance sheet | ||||||||
| Cash & equivalents | $11.06M | $15.51M | $32.70M | $38.46M | $29.18M | $32.28M | $44.47M | $16.36M |
| Receivables | $154.93M | $158.39M | $165.86M | $187.51M | $226.46M | $195.79M | $207.32M | $211.19M |
| Inventory | $64.79M | $88.59M | $87.61M | $92.02M | $101.81M | $117.66M | $125.93M | $129.16M |
| Current assets | $294.28M | $283.15M | $308.31M | $338.21M | $382.57M | $377.08M | $408.67M | $407.18M |
| PP&E, netmay include right-of-use assets (IFRS) | $61.09M | $74.04M | $74.58M | $75.34M | $74.90M | $74.56M | $74.57M | $74.56M |
| Goodwill | $36.07M | $112.16M | $112.16M | $112.16M | $112.16M | $112.16M | $112.16M | $112.16M |
| Intangibles | $87.29M | $178.64M | $181.17M | $181.82M | $176.29M | $175.77M | $176.89M | $174.45M |
| Total assets | $560.36M | $734.88M | $763.65M | $798.21M | $835.20M | $827.26M | $852.55M | $836.13M |
| Current liabilities | $328.64M | $299.72M | $337.99M | $332.31M | $288.78M | $295.86M | $329.31M | $332.97M |
| Short-term debt | $90.06M | $85.13M | $119.73M | $95.64M | $119.19M | $121.18M | $136.75M | $142.61M |
| Long-term debt | $34.16M | $53.80M | $38.20M | $75.69M | $66.91M | $46.06M | $42.10M | $20.48M |
| Total debt | $124.22M | $138.94M | $157.93M | $171.34M | $186.11M | $167.24M | $178.85M | $163.08M |
| Total liabilities | $453.75M | $446.55M | $468.43M | $453.24M | $488.87M | $481.23M | $501.17M | $487.60M |
| Shareholders' equity | $76.41M | $258.67M | $265.44M | $308.46M | $309.55M | $309.48M | $315.04M | $313.35M |
| Net debt | $113.15M | $123.43M | $125.23M | $132.88M | $156.93M | $134.96M | $134.38M | $146.72M |
| Cash flow statement | ||||||||
| Operating cash flow | $17.39M | $14.38M | $26.77M | $23.34M | -$5.36M | $5.16M | $23.26M | -$17.39M |
| Capital expenditure | -$12,473 | $672,115 | $430,670 | $1.28M | $2.66M | $1.28M | $2.02M | $1.70M |
| Free cash flow | $17.40M | $13.70M | $26.34M | $22.06M | -$8.01M | $3.88M | $21.24M | -$19.09M |
| Investing cash flow | -$2.80M | -$1.26M | $1.49M | -$2.50M | -$5.39M | $271,763 | -$295,058 | -$1.37M |
| Financing cash flow | -$17.99M | -$28.71M | -$25.71M | -$12.68M | $6.49M | -$18.80M | $5.32M | $10.90M |
| Stock-based compensation | — | $533 | $1.03M | $1.01M | $1.53M | $809,585 | $2.65M | $2.95M |
| Dividends paid | — | — | $0 | $0 | — | — | $0 | $23,188 |
| Share buybacks | — | — | $0 | $0 | — | — | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 20 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.